Search Results for: UBC

1079 interactions involving UBC - ubiquitin C found:

Sort by: Symbol Number of Pathways Number of Drugs Number of Diseases
Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
CHD3 chromodomain helicase DNA binding protein 3
  • HDACs deacetylate histones
  • ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression
  • SUMOylation of chromatin organization proteins
  • Regulation of TP53 Activity through Acetylation
  • RNA Polymerase I Transcription Initiation
  • Regulation of PTEN gene transcription
  • Regulation of PTEN gene transcription
  • Potential therapeutics for SARS
  • Regulation of endogenous retroelements by KRAB-ZFP proteins
  • Transcriptional regulation of brown and beige adipocyte differentiation by EBF2
  • Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs)
CHEK1 checkpoint kinase 1
  • Signaling by SCF-KIT
  • Activation of ATR in response to replication stress
  • Processing of DNA double-strand break ends
  • Presynaptic phase of homologous DNA pairing and strand exchange
  • TP53 Regulates Transcription of DNA Repair Genes
  • Regulation of TP53 Activity through Phosphorylation
  • G2/M DNA damage checkpoint
  • Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A
  • Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
  • Transcriptional Regulation by E2F6
  • XL844
  • Enzastaurin
  • CHIR-124
  • N-{5-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-1H-PYRROLO[2,3-B]PYRIDIN-3-YL}NICOTINAMIDE
  • 3-(5-{[4-(AMINOMETHYL)PIPERIDIN-1-YL]METHYL}-1H-INDOL-2-YL)QUINOLIN-2(1H)-ONE
  • 2,2'-{[9-(HYDROXYIMINO)-9H-FLUORENE-2,7-DIYL]BIS(OXY)}DIACETIC ACID
  • (2S)-1-AMINO-3-[(5-NITROQUINOLIN-8-YL)AMINO]PROPAN-2-OL
  • 2-(cyclohexylamino)benzoic acid
  • 3-(5-{[4-(AMINOMETHYL)PIPERIDIN-1-YL]METHYL}-1H-INDOL-2-YL)-1H-INDAZOLE-6-CARBONITRILE
  • (3Z)-6-(4-HYDROXY-3-METHOXYPHENYL)-3-(1H-PYRROL-2-YLMETHYLENE)-1,3-DIHYDRO-2H-INDOL-2-ONE
  • 5-ETHYL-3-METHYL-1,5-DIHYDRO-4H-PYRAZOLO[4,3-C]QUINOLIN-4-ONE
  • (5-{3-[5-(PIPERIDIN-1-YLMETHYL)-1H-INDOL-2-YL]-1H-INDAZOL-6-YL}-2H-1,2,3-TRIAZOL-4-YL)METHANOL
  • 1-(5-CHLORO-2-METHOXYPHENYL)-3-{6-[2-(DIMETHYLAMINO)-1-METHYLETHOXY]PYRAZIN-2-YL}UREA
  • (3-ENDO)-8-METHYL-8-AZABICYCLO[3.2.1]OCT-3-YL 1H-PYRROLO[2,3-B]PYRIDINE-3-CARBOXYLATE
  • 18-CHLORO-11,12,13,14-TETRAHYDRO-1H,10H-8,4-(AZENO)-9,15,1,3,6-BENZODIOXATRIAZACYCLOHEPTADECIN-2-ONE
  • 1-(5-CHLORO-2,4-DIMETHOXYPHENYL)-3-(5-CYANOPYRAZIN-2-YL)UREA
  • 4-(6-{[(4-METHYLCYCLOHEXYL)AMINO]METHYL}-1,4-DIHYDROINDENO[1,2-C]PYRAZOL-3-YL)BENZOIC ACID
  • 4-[3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOL-6-YL]-2-METHOXYPHENOL
  • (2R)-1-[(5,6-DIPHENYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)AMINO]PROPAN-2-OL
  • (2R)-3-{[(4Z)-5,6-DIPHENYL-6,7-DIHYDRO-4H-PYRROLO[2,3-D]PYRIMIDIN-4-YLIDENE]AMINO}PROPANE-1,2-DIOL
  • N-(5,6-DIPHENYLFURO[2,3-D]PYRIMIDIN-4-YL)GLYCINE
  • (5,6-DIPHENYL-FURO[2,3-D]PYRIMIDIN-4-YLAMINO)-ACETIC
  • 3-AMINO-3-BENZYL-[4.3.0]BICYCLO-1,6-DIAZANONAN-2-ONE
  • 3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOLE
  • 2-[5,6-BIS-(4-METHOXY-PHENYL)-FURO[2,3-D]PYRIMIDIN-4-YLAMINO]-ETHANOL
  • 2-[(5,6-DIPHENYLFURO[2,3-D]PYRIMIDIN-4-YL)AMINO]ETHANOL
  • REL-(9R,12S)-9,10,11,12-TETRAHYDRO-9,12-EPOXY-1H-DIINDOLO[1,2,3-FG:3',2',1'-KL]PYRROLO[3,4-I][1,6]BENZODIAZOCINE-1,3(2H)-DIONE
  • 1-[(2S)-4-(5-phenyl-1H-pyrazolo[3,4-b]pyridin-4-yl)morpholin-2-yl]methanamine
  • N-(4-OXO-5,6,7,8-TETRAHYDRO-4H-[1,3]THIAZOLO[5,4-C]AZEPIN-2-YL)ACETAMIDE
  • 5,6,7,8-TETRAHYDRO[1]BENZOTHIENO[2,3-D]PYRIMIDIN-4(3H)-ONE
  • [4-amino-2-(tert-butylamino)-1,3-thiazol-5-yl](phenyl)methanone
  • 2-(methylsulfanyl)-5-(thiophen-2-ylmethyl)-1H-imidazol-4-ol
  • 6-MORPHOLIN-4-YL-9H-PURINE
  • 1-[(2S)-4-(5-BROMO-1H-PYRAZOLO[3,4-B]PYRIDIN-4-YL)MORPHOLIN-2-YL]METHANAMINE
  • Prexasertib
  • Fostamatinib
  • LY-2608204
  • PF-477736
CHGA chromogranin A
  • Antimicrobial peptides
CHP1 calcineurin like EF-hand protein 1
  • Hyaluronan degradation
  • Calcium citrate
  • Calcium Phosphate
  • Calcium phosphate dihydrate
CHRAC1 chromatin accessibility complex subunit 1
CHUK component of inhibitor of nuclear factor kappa B kinase complex
  • Activation of NF-kappaB in B cells
  • Activation of NF-kappaB in B cells
  • ER-Phagosome pathway
  • NOD1/2 Signaling Pathway
  • TICAM1, RIP1-mediated IKK complex recruitment
  • RIP-mediated NFkB activation via ZBP1
  • AKT phosphorylates targets in the cytosol
  • Downstream TCR signaling
  • FCERI mediated NF-kB activation
  • TAK1-dependent IKK and NF-kappa-B activation
  • Regulation of TNFR1 signaling
  • TNFR1-induced NF-kappa-B signaling pathway
  • IKBKB deficiency causes SCID
  • IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR)
  • IkBA variant leads to EDA-ID
  • Dectin-1 mediated noncanonical NF-kB signaling
  • CLEC7A (Dectin-1) signaling
  • Constitutive Signaling by AKT1 E17K in Cancer
  • NIK-->noncanonical NF-kB signaling
  • MAP3K8 (TPL2)-dependent MAPK1/3 activation
  • Interleukin-1 signaling
  • TRAF6 mediated NF-kB activation
  • NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
  • IRAK1 recruits IKK complex
  • IKK complex recruitment mediated by RIP1
  • SARS-CoV-2 activates/modulates innate and adaptive immune responses
  • IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
  • Regulation of NF-kappa B signaling
  • PKR-mediated signaling
  • SLC15A4:TASL-dependent IRF5 activation
  • Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells
  • Modulation of host responses by IFN-stimulated genes
  • Aminosalicylic acid
  • Mesalazine
  • Acetylcysteine
  • Cocoon syndrome
CIAO1 cytosolic iron-sulfur assembly component 1
  • Cytosolic iron-sulfur cluster assembly
CIRBP cold inducible RNA binding protein
CLN8 CLN8 transmembrane ER and ERGIC protein
  • Progressive myoclonic epilepsy (PME), including: Lafora disease (LBD); Unverricht-Lundborg disease (ULD); Neuronal ceroid lipofuscinoses (NCL); Type I sialidosis; Action myoclonus-renal failure syndrome (AMRF); Type III Gaucher disease (GD)
  • Neuronal ceroid lipofuscinosis, including: Infantile Neuronal Ceroid Lipofuscinosis (INCL)/ Santavuori-Haltia Disease (CLN1); Late-Infantile Neuronal Ceroid Lipofuscinosis (LINCL)/ Jansky-Bielschowsky Disease (CLN2); Juvenile Neuronal Ceroid Lipofuscinosis (JNCL)/Batten Disease/ Spielmeyer-Vogt Disease (CLN3); Adult Neuronal Ceroid Lipofuscinosis (ANCL)/ Kufs Disease (CLN4); LINCL variant (CLN5, CLN6, CLN7, CLN8); Batten Disease variant (CLN9); Congenital NCL (CLN10)
CLNS1A chloride nucleotide-sensitive channel 1A
  • snRNP Assembly
CLU clusterin
  • Platelet degranulation
  • Terminal pathway of complement
  • Antimicrobial peptides
  • Regulation of Complement cascade
  • Zinc
  • Copper
  • Zinc acetate
  • Zinc chloride
  • Zinc sulfate, unspecified form
CMSS1 cms1 ribosomal small subunit homolog
CNP 2'',3''-cyclic nucleotide 3'' phosphodiesterase
COL1A1 collagen type I alpha 1 chain
  • GPVI-mediated activation cascade
  • Collagen degradation
  • Collagen degradation
  • Fibronectin matrix formation
  • Collagen biosynthesis and modifying enzymes
  • Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
  • Assembly of collagen fibrils and other multimeric structures
  • Cell surface interactions at the vascular wall
  • Integrin cell surface interactions
  • Integrin cell surface interactions
  • Anchoring fibril formation
  • Crosslinking of collagen fibrils
  • Syndecan interactions
  • Non-integrin membrane-ECM interactions
  • ECM proteoglycans
  • ECM proteoglycans
  • Scavenging by Class A Receptors
  • GP1b-IX-V activation signalling
  • Platelet Adhesion to exposed collagen
  • Platelet Adhesion to exposed collagen
  • Platelet Aggregation (Plug Formation)
  • MET activates PTK2 signaling
  • RUNX2 regulates osteoblast differentiation
  • Collagen chain trimerization
  • Enhanced cleavage of VWF variant by ADAMTS13
  • Enhanced binding of GP1BA variant to VWF multimer:collagen
  • Defective VWF cleavage by ADAMTS13 variant
  • Defective VWF binding to collagen type I
  • Defective binding of VWF variant to GPIb:IX:V
  • Developmental Lineage of Pancreatic Ductal Cells
  • Collagenase clostridium histolyticum
  • Halofuginone
  • Clove oil
  • Vonicog alfa
  • Von Willebrand factor human
  • Osteogenesis imperfecta
  • Ehlers-Danlos syndrome (EDS), including: EDS classical type (EDS1/2); EDS hypermobility type (EDS3); EDS vascular type (EDS4); EDS kyphoscoliosis type (EDS6); EDS arthrochalasia type (EDS7A/7B); EDS dermatospraxis type (EDS7C); EDS autosomal recessive cardiac valvular form (EDSCV); EDS musculocontractural type (EDSMC); EDS progeroid form (EDSP); Tenascin-X deficiency (TNXD); Brittle cornea syndrome (EDS6B); EDS-like spondylocheiro dysplasia (SCD-EDS)
  • Infantile cortical hyperostosis; Caffey disease
COMMD9 COMM domain containing 9
  • Neutrophil degranulation
  • Neddylation
COPB1 coat protein complex I subunit beta 1
  • Neutrophil degranulation
  • COPI-mediated anterograde transport
  • COPI-dependent Golgi-to-ER retrograde traffic
COPS2 COP9 signalosome subunit 2
  • DNA Damage Recognition in GG-NER
  • Formation of TC-NER Pre-Incision Complex
  • Cargo recognition for clathrin-mediated endocytosis
  • Neddylation
  • RHOBTB1 GTPase cycle
COPS3 COP9 signalosome subunit 3
  • DNA Damage Recognition in GG-NER
  • Formation of TC-NER Pre-Incision Complex
  • Cargo recognition for clathrin-mediated endocytosis
  • Neddylation
COPS6 COP9 signalosome subunit 6
  • DNA Damage Recognition in GG-NER
  • Formation of TC-NER Pre-Incision Complex
  • Cargo recognition for clathrin-mediated endocytosis
  • Neddylation
COPS7B COP9 signalosome subunit 7B
  • DNA Damage Recognition in GG-NER
  • Formation of TC-NER Pre-Incision Complex
  • Cargo recognition for clathrin-mediated endocytosis
  • Neddylation

Page 9 out of 54 pages